Nevertheless, Compound 3 (diABZI), for instance, induced potent T cell responses and improved overall survival in a subcutaneous CT26 colorectal cancer mouse model after intravenous (IV) injection.[61b] Additionally, diABZI showed increased tumor cell apoptosis in vitro and in vivo together with an enhanced expression of tumor antigens.[64] Similarly, MSA‐2, another systemic STING agonist, holds promise for inducing tumor regression through oral administration. The gene discussed is STING1; the disease is colorectal cancer.